- Drink Up: Coffee Won’t Affect Your Heart Rhythms
- Feds Propose Overhaul of U.S. Organ Transplant System
- Living Near Noisy Roads Can Raise Your Blood Pressure
- New Parasite Is Killing Sea Otters, and Might Pose Threat to People
- Health Highlights: March 23, 2023
- When Kids Lose a Parent, New Therapy Might Prevent Long-Term Mental Harm
- Dealing With Caregiver Stress & Burnout: A Guide
- ‘Muted’ Immune Response May Explain Why COVID Is Tougher for Obese People
- New Technique 80% Effective in Selecting a Baby’s Gender
- Florida Bill Would Ban Elementary School Kids From Learning About Menstruation
Imbruvica Approved for Mantle Cell Lymphoma
WEDNESDAY, Nov. 13Imbruvica (ibrutinib) has been approved by the U.S. Food and Drug Administration to treat mantle cell lymphoma (MCL), a rare but aggressive form of blood cancer.
MCL represents about six percent of non-Hodgkin lymphoma cases, the agency said Wednesday in a news release. By the time it’s usually diagnosed, it has spread to other areas such as the lymph nodes or bone marrow.
Imbruvica, designed to inhibit an enzyme that cancer cells need to spread, was granted the FDA’s rare “breakthrough therapy” status as a drug that promises to offer a “substantial improvement over available therapies for patients with serious or life-threatening diseases,” the agency said.
Imbruvica was evaluated in a study of 111 participants. Of those who took the drug daily, 66 percent had their cancer shrink or disappear, the FDA said. The most common side effects included: low blood platelets, diarrhea, low white blood cells, anemia, fatigue, musculoskeletal pain, swelling and upper respiratory infection.
Imbruvica is co-marketed by Sunnyvale, Calif.-based Pharmacyclics, and Raritan, N.J.-based Janssen Biotech.
More information
To learn more about non-Hodgkin lymphoma, visit Medline Plus.
Source: HealthDay
Copyright © 2023 HealthDay. All rights reserved.
Related
-
New Technique 80% Effective in Selecting a Baby’s GenderIt’s a controversial notion, but couples undergoing fertility treatments...
- March 22, 2023
-
Florida Bill Would Ban Elementary School Kids From Learning About MenstruationA proposed bill in Florida would prevent children from...
- March 22, 2023
-
Birth Control Pills Tied to Slight Rise in Breast Cancer Risk, Regardless of FormulationTaking progestogen-only birth control pills comes with a slightly...
- March 22, 2023
-
IUDs, Contraceptive Implants Tough to Access for Women on MedicaidPeople covered by Medicaid insurance may not have easy...
- March 20, 2023
